Pharmathen's new Research and Development Centre in Pallini, Athens

Pharmathen S.A announced the establishment of a new Research and Development Centre in Pallini, Athens. The new Research Centre will focus on developing Generic molecules and is expected to significantly reinforce Pharmathen's already excellent R&D capabilities. Pharmathen is one of the strongest generic developer in Europe and with the operation of the new facility the company's R&D activities will be further increased. The new state-of-the-art centre is equipped with the most technologically advanced instruments and laboratory machinery. Furthermore the new R&D centre will initially employ 70 scientists with advanced academic qualifications and long-term experience in research.

The establishment of the new research centre is the latest addition in a series of investments which have taken place over the last three years including the API R&D centre in Thessaloniki; the Innovative Formulation Laboratory also in Thessaloniki; the new manufacturing plant in Pikermi, Athens; and the new manufacturing plant in Sapes, Northern Greece, which is currently under construction and it is expected to be operational by the end of 2008. The new R&D centre will be in close cooperation with the other research units of Pharmathen.

Pharmathen is already a fully integrated company from API to finished formulations and the new facility will reinforce further its integration, allowing the company to provide a fully backwardly integrated quality service to its clients worldwide.

About Pharmathen Pharmaceuticals
Located in Athens, Greece, Pharmathen Pharmaceuticals is a private pharmaceutical company focused on developing and marketing of health care products, with a strong position in generics. Founded in 1969 by Dr. Nicolas Katsos, it is one of the fastest growing pharmaceutical companies in Greece.

With a long history of development and manufacturing of generic products, Pharmathen has emerged as one of the largest generic development companies in Europe with a development pipeline of ten generic molecules a year.

For further information, please visit www.pharmathen.gr.

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...